Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and ...
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: TheStreet.com
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations Safety and tolerability findings included: Day 42 Data Show Higher AUC, Cavg, and Cmax vs Day 1, with ~2.1x Accumulation Supporting Sustained Drug Exposure, Consistent Tolerability, and Clinically Meaningful Response NEW YORK March 24, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) today reported positive pharmacokinetic (PK), safety, and clinical activity data for HT-001, demonstrating a ~77% increase in systemic drug exposure following repeat dosing, minimal systemic absorption relative to oral formulations, a favorable safety profile with no serious adverse events, and encouraging reductions in symptom severity. In addition, HT-001 demonstrated encouraging clinical activity, with treated subjects exhibiting meaningful reductions in symptom severity and sustained response over the treatment period. These efficacy observa
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug DiscoveryPR Newswire
- Hoth Therapeutics (HOTH) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic AbsorptionPR Newswire
- Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model [Yahoo! Finance]Yahoo! Finance
HOTH
Sec Filings
- 3/27/26 - Form 10-K
- 1/16/26 - Form 8-K
- HOTH's page on the SEC website